Discover how India’s API pharmaceutical market is embracing sustainability through green chemistry innovations and strategic industry advancements.
In the realm of pharmaceuticals, green is emerging as the new standard, particularly in India’s API market. This shift towards sustainability presents manufacturers with an opportunity to elevate their offerings and expand their global footprint. The emphasis on green chemistry has catalyzed research and development efforts within the API domain, leading to the creation of innovative synthetic pathways and eco-friendly alternatives. Key advancements such as flow chemistry and green chemistry methodologies have garnered attention for their sustainability benefits, aligning with both market demands and regulatory requirements.
Arun Doshi, chairman and managing director of Surya Lifesciences, underscores the industry’s commitment to environmental stewardship, stating, “We are constantly working on process developments with an eye toward environmental safety, and we impose strict control over our effluents.” This dedication to sustainable practices not only enhances environmental protection but also bolsters industry credibility.
As manufacturers pivot towards offering green and specialized products, the API market presents myriad opportunities for value addition. A notable trend involves formulation companies diversifying into API production and vice versa, a strategic move poised to enhance industry resilience. This convergence is poised to elevate India’s pharmaceutical sector, aligning with the nation’s aspirations of fostering specialization and customization within the industry.
The burgeoning expansion of India’s API sector, particularly through heightened exports, is set to benefit excipient and intermediate producers in the country directly. According to Beroe, India’s excipient market is experiencing robust growth, outpacing the global average with a growth rate of 10% to 12%.
Factors fueling this growth include advancements in functional excipients, increased utilization of biologics, and the rising adoption of orphan drugs. Recognizing the pivotal role of excipients in formulation integrity, many companies are prioritizing excipient innovation to address challenges such as segregation, low dissolution, and poor bioavailability.
While price remains a key consideration in excipient procurement, India’s competitive edge lies in its ability to offer products at a 5% to 7% lower cost compared to developed markets. However, in an industry where quality is non-negotiable, the focus on product safety and performance remains paramount. Chitra Shah of Arihant Innochem emphasizes the importance of safe and multifunctional excipients, stating, “As machine technology advances, excipients with superior performance to withstand the rigors of the manufacturing process while delivering a robust formulation are in high demand.”
Innovation within the excipient space is centered on exploring new applications, enhancing morphology, and diversifying routes of administration. Areas of focus include hot melt extrusion, nanotechnology, implants, and injectable deliveries, with pulmonary delivery and nutraceuticals emerging as key frontiers.
With demand for excipients poised to surge in the coming years, Indian firms must navigate stringent regulatory frameworks and embrace technological advancements such as Pharma 4.0 to sustain global competitiveness. By prioritizing innovation, sustainability, and regulatory compliance, India’s pharmaceutical industry can chart a path toward enduring growth and leadership in the global arena.
API Pharmaceutical
API Pharmaceutical
Comments are closed.
